Biotech News

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics (ESPR)Esperion Therapeutics2026-05-14 20:30 ESTCompany update

ANN ARBOR, Mich., May 14, 2026 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 12 2026, the Company granted 23 new employees 260,000 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used

Related news

ESPREsperion Therapeutics2026-05-26 12:00 EST

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

ESPREsperion Therapeutics2026-05-01 11:00 EST

Esperion to be Acquired by ARCHIMED

View all latest news

Esperion Therapeutics

Oral Cardiometabolic Medicines Esperion Therapeutics develops and commercializes oral therapies for cardiovascular risk reduction and is expanding toward rare hepatic and renal diseases. Its scientific foundation is inhibition of ATP citrate lyase. Bempedoic Acid Franchise NEXLETOL and NEXLIZET are once-daily, non-statin...

Recent company news

ESPREsperion Therapeutics2026-05-26 12:00 EST

Esperion Presents New Data from CLEAR Outcomes and the CLEAR PATH Phase 2 Pediatric Study at the European Atherosclerosis Society Congress 2026

ESPREsperion Therapeutics2026-05-14 20:30 EST

Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ESPREsperion Therapeutics2026-05-13 12:00 EST

Esperion Announces Two New Analyses Supporting Bempedoic Acid to Reduce LDL-C Levels to be Presented at the European Atherosclerosis Society (EAS) Congress 2026

ESPREsperion Therapeutics2026-05-01 11:00 EST

Esperion to be Acquired by ARCHIMED

ESPREsperion Therapeutics2026-04-23 12:00 EST

Esperion to Report First Quarter 2026 Financial Results on May 7

Stock data

Close: 3.18 USD
Market cap: 808.34M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States